Cell and Gene Therapy (CGT) space bears the incredible biological promise together with several important challenges. In response, a group of companies are developing software, data science, and hardware solutions that seek to address the challenges associated with CGT discovery, manufacturing, and supply. The end goal is to make ‘better’ therapies available to a wider patient population at a lower price. Based on our in-house research, we have compiled a ‘living’ list of emerging frontier technology and life sciences companies developing tools for the CGT space.
What is Computer-Aided Biology (CAB) and why is the “Digital to Physical” transition so important? How is the emerging CAB ecosystem evolving and how many companies are striving towards the same goal of an integrated suite of tools? What is the data journey? Why is metadata important to artificial intelligence (AI) within the biological sciences and why is it so challenging for a researcher to define what metadata to collect? Find all of this and more by exploring our whitepapers.